The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth - PubMed (original) (raw)

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

Jana Divisova et al. Breast Cancer Res Treat. 2006 Aug.

Abstract

Mammary gland development is dependent upon the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis, this same axis has also been implicated in breast cancer progression. In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft growth. Intraperitoneal administration of pegvisomant resulted in a 60% suppression of hepatic IGF-I mRNA levels and upto a 70-80% reduction of serum IGF-I levels. Pegvisomant administration to virgin female mice caused a significant delay of mammary ductal outgrowth that was associated with a decrease in the number of terminal end buds and reduced branching and complexity of the gland. This effect of pegvisomant was mediated by a complete inhibition of both GH and IGF-IR-mediated signaling within the gland. In breast cancer xenograft studies, pegvisomant caused shrinkage of MCF-7 xenografts, with an initial 30% reduction in tumor volume, which was associated with a 2-fold reduction in proliferation and a 2-fold induction of apoptosis. Long-term growth inhibition of MCF-7 xenografts was noted. In contrast, pegvisomant had no effect on MDA-231 or MDA-435 xenografts, consistent with primary growth of these xenografts being unresponsive to IGF-I both in vitro and in vivo. In MCF-7 xenografts that regressed, pegvisomant had only minor effects upon GHR and IGF-IR signaling. This data supports previous studies indicating a role for GH/IGF in mammary gland development, and suggests that pegvisomant maybe useful for the prevention and/or treatment of estrogen receptor positive breast cancer.

PubMed Disclaimer

Cited by

Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivo.
Basu R, Qian Y, Mathes S, Terry J, Arnett N, Riddell T, Stevens A, Funk K, Bell S, Bokal Z, Batten C, Smith C, Mendez-Gibson I, Duran-Ortiz S, Lach G, Mora-Criollo PA, Kulkarni P, Davis E, Teaford E, Berryman DE, List EO, Neggers S, Kopchick JJ. Basu R, et al. Front Oncol. 2022 Jul 5;12:936145. doi: 10.3389/fonc.2022.936145. eCollection 2022. Front Oncol. 2022. PMID: 35865483 Free PMC article.
From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.
Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F. Clevenger CV, et al. J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):147-56. doi: 10.1007/s10911-008-9074-8. Epub 2008 Feb 2. J Mammary Gland Biol Neoplasia. 2008. PMID: 18246318 Review.
Genetic Code Expansion Enables Site-Specific PEGylation of a Human Growth Hormone Receptor Antagonist through Click Chemistry.
Tamshen K, Wang Y, Jamieson SMF, Perry JK, Maynard HD. Tamshen K, et al. Bioconjug Chem. 2020 Sep 16;31(9):2179-2190. doi: 10.1021/acs.bioconjchem.0c00365. Epub 2020 Sep 2. Bioconjug Chem. 2020. PMID: 32786367 Free PMC article.
Canine mammary tumors as a model for human disease.
Abdelmegeed SM, Mohammed S. Abdelmegeed SM, et al. Oncol Lett. 2018 Jun;15(6):8195-8205. doi: 10.3892/ol.2018.8411. Epub 2018 Apr 2. Oncol Lett. 2018. PMID: 29928319 Free PMC article. Review.
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.
Kleinberg DL, Wood TL, Furth PA, Lee AV. Kleinberg DL, et al. Endocr Rev. 2009 Feb;30(1):51-74. doi: 10.1210/er.2008-0022. Epub 2008 Dec 15. Endocr Rev. 2009. PMID: 19075184 Free PMC article. Review.

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth - PubMed (original) (raw)